Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary Protein Oral Delivery (POD) technology for the delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching a Phase 2b multi-center trial under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.

To review the safety data on Oramed's Phase 2a FDA trial on ORMD-0801 on patients with type 2 diabetes, click here.

Oramed in the News

March 30th, 2014: Reuters - Clinical trials hold promise for world's first oral insulin pill

January 30th,  2014: Bloomberg - Oral Diabetes Medicine Shows Promist in Study of Oramed Pill 

For more of Oramed in the news, please click here.

Events

GTC Diabetes Summit:

Cambridge, MA: April 23-25, 2014                                                                            

For more Oramed events, please click here.

Press Releases

 

 

April 10, 2014

Oramed Granted Patent in Hong Kong for Oral Administration of Insulin

...read more>>

 

March 27, 2014

Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes

...read more>>

 

 

 

March 11, 2014

Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide

...read more>>

 

 

March 6, 2014

Oramed to Present at Upcoming Conferences

...read more>>

 

 

March 3, 2014

Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014

...read more>>

 

 

Feb 10, 2014

Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule

...read more>>

 

Jan 30, 2014

 

Oramed Announces Successful FDA Phase 2a Clinical Trial Results

...read more>>

 

Jan 27, 2014

Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock Exchange

...read more>>

 

Jan 2, 2014

Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins

...read more>>

 

Dec 20, 2013

Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes: Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January

...read more>>

 

Dec 10, 2013

Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel

...read more>>

 

 

 
Press Center | Terms & Conditions | Privacy Statement Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed